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Short communication: Pegbovigrastim treatment in vivo does not impact on granulocyte 1 
capability to migrate to endometrial cells and kill bacteria in vitro. By Tombácz et al. The in vivo 2 
effects of pegylated bovine granulocyte colony stimulating factor (pegbovigrastim, Imrestor™ Elanco 3 
Animal Health, Greenfield, IN) are well described, however, its effects on granulocyte function on a 4 
per cell basis are not yet fully elucidated. We applied a recently developed co-culture and bactericidal 5 
assay to assess migratory and bacterial killing activities of granulocytes isolated from animals treated 6 
with pegbovigrastim (n=6) or placebo (n=5). While treatment increased circulating neutrophil 7 
granulocyte and monocyte concentrations in treated animals, it did not affect granulocyte function in 8 
vitro. We suggest that the benefits of treatment are due to increased production of functional 9 
granulocytes. 10 
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ABSTRACT 27 
In periparturient dairy cows, immune suppression, resulting in decreased neutrophil numbers and 28 
function, leads to increased susceptibility to postpartum conditions such as mastitis, retained placenta 29 
and metritis. The administration of polyethylene glycol-conjugated bovine granulocyte colony 30 
stimulating factor (pegbovigrastim, Imrestor™ Elanco Animal Health, Greenfield, IN) 7 days before and 31 
within 24 hours of calving, effectively improves granulocyte production and function in vivo as well as 32 
in the milk. A recently developed co-culture assay was adapted for use with endometrial epithelial cells 33 
to assess the effects of pegbovigrastim application on directed granulocyte migration and bactericidal 34 
activity in vitro on a per cell basis in endometrial cell cultures. Granulocytes from treated and untreated 35 
periparturient cows (6 and 5 per group, respectively) were evaluated for their ability to migrate to and 36 
kill bacteria after treatment, in context of the infected endometrium. We hypothesized that in addition to 37 
increasing the absolute concentration of circulating neutrophil granulocytes, pegbovigrastim treatment 38 
in vivo alters the ability of granulocytes to migrate to endometrial cells in vitro. The results clearly show 39 
a significant increase in the total concentration of granulocytes and monocytes between the two treatment 40 
groups as early as two days after the first injection, and this increased between the samples taken two 41 
days after calving. No migratory or killing differences were identified between granulocytes of both 42 
groups, suggesting that pegbovigrastim-induced granulocytes were as effective as non-induced cells. 43 
This may also be due to the absence of negative energy balance in the study animals and leads us to 44 
conclude that the positive effects seen in vivo are most likely based on the larger number of granulocytes 45 
being present rather than a direct effect of pegbovigrastim treatment on the functionality of cells for the 46 
parameters tested in this study. 47 
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ABBREVIATIONS 53 
BHBA: β-hydroxy-butyric acid 54 
CBC: Complete blood count 55 
CFU: Colony forming unit 56 
CXCL8: Chemokine (C-X-C motif) ligand 8 57 
G-CSF: Granulocyte colony-stimulating factor 58 
MOI: Multiplicity of Infection 59 
NEFA: Non-esterified fatty acid 60 
PEG: Polyethylene-glycol 61 
WBC: White blood cell 62 
 63 
 64 
Short communication 65 
INTRODUCTION 66 
Puerperal metritis and postpartum endometritis are prevalent conditions in dairy cattle, 67 
compromising animal welfare, leading to economic damage by reducing milk production, and causing 68 
delayed fertility or infertility. In most cases, these conditions are caused by bacterial infections, 69 
facilitated by the presence of tissue damage caused by retained placenta, stillbirth, twins, caesarean 70 
section, and aggravated by the innate immune response of the host to bacteria and endotoxin (Carneiro 71 
et al., 2016). The treatment of puerperal uterine disease relies heavily on antibiotics and although in 72 
some cases necessary for the welfare of the animal, the results are unreliable (Pyorala et al., 2014). Given 73 
the increasing drive to reduce the use of antibiotics in food producing animals, new treatment 74 
possibilities are currently being investigated that impact on immune cell subsets. The first immune cells 75 
responding to damage signals from compromised tissue and infection are polymorphonuclear cells. 76 
These cells are recruited predominantly by the chemokine CXCL (IL-)8, produced as a direct response 77 
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to innate recognition of Gram-negative bacterial infection by a variety of cells, including endothelial 78 
cells (Cronin et al., 2016).  79 
Periparturient dairy cows experience a fluctuation in neutrophil count and decrease in function, 80 
starting before calving, remaining low and slowly reaching normal levels again by the fourth week of 81 
lactation (Kehrli et al., 1989). This phenomenon is associated with increased susceptibility to postpartum 82 
conditions, including retained placenta, acute puerperal metritis, and chronic endometritis (Kehrli et al., 83 
1991, Detilleux et al., 1995, Hammon et al., 2006). The immunosuppression results from both 84 
physiological (maintaining pregnancy) and pathophysiological events (negative energy balance). 85 
Elevated ketone bodies can directly impair some neutrophil functions, increasing disease susceptibility 86 
(Hoeben et al., 1997, Hoeben et al., 2000, Grinberg et al., 2008). 87 
Prophylactic use of bovine granulocyte-colony stimulating factor (G-CSF) has the potential to pre-88 
emptively increase neutrophil numbers and modulate their function ahead of parturition (Kehrli et al., 89 
1991). Pegbovigrastim (Imrestor™ Elanco Animal Health, Greenfield, IN), a form of G-CSF covalently 90 
bound to polyethylene-glycol to increase its half-life, is effective in maintaining increased neutrophil 91 
granulocyte levels, compensating for decreased bacterial killing (Kimura et al., 2014). In addition, 92 
pegbovigrastim has been shown to have an impact on gene expression in neutrophils, affecting gene 93 
families related to neutrophil function, migration, interaction with pathogens, and cellular survival 94 
(Heiser et al., 2018).  95 
As well as reducing the incidence of clinical and experimental mastitis (Powell et al., 2018), 96 
pegbovigrastim treatment decreased the risk of failure to return to oestrus within 80 days of calving 97 
(Canning et al., 2017). A recent study found a reduction in the incidence of retained placenta and mastitis 98 
as a result of label use of pegbovigrastim, however, metritis was reported to occur more frequently in 99 
treated animals (Ruiz et al., 2017). In a different study, pegbovigrastim treatment was shown to reduce 100 
the incidence of acute puerperal metritis in primiparous dairy cows, as well as the number of antibiotic 101 
doses required for treatment (Freick et al., 2018). An increasing body of clinical data are available on 102 
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the in vivo effects of pegbovigrastim use (Zinicola et al., 2018), however, its action on granulocytes on 103 
a per-cell base is yet to be determined. 104 
The objective of this study was to investigate the effects of Imrestor™ (pegbovigrastim) on 105 
bacterial clearance in the context of the endometrium of cows on a per-cell basis. Blood-derived 106 
granulocytes collected from pegbovigrastim or placebo treated periparturient animals were examined in 107 
vitro in a newly developed co-culture assay to observe their migration and bactericidal activity towards 108 
infected endometrial epithelial cells. 109 
 110 
MATERIALS AND METHODS 111 
Our study was designed to compare functional differences between granulocytes isolated from 112 
periparturient cattle treated with pegbovigrastim and placebo. In our experience, a minimum of 6 113 
biological repeats is necessary in order to overcome the natural variation in animal responsiveness to 114 
obtain significant p-values (with significance set at p = 0.05) with regards to cytokine production and 115 
bacterial killing (Conejeros et al., 2015, Joekel et al., 2015, Gibson et al., 2016, Jensen et al., 2016). The 116 
study was conducted at the Royal Veterinary College’s Bolton Park (Potter Bar, UK) research and 117 
teaching farm, under the authority of the UK Animal Scientific Procedures Act (ASPA, 1986). Although 118 
no formal quality standard is claimed, the study was conducted in line with the principles of Good 119 
Clinical Practice Guidelines and laboratory work was conducted in accordance with the Research 120 
Councils UK Policy and Guidelines on the Governance of Good Research Conduct. 121 
Animals (n=12) enrolled in the study (autumn 2016 to spring 2017) were pregnant, multiparous 122 
Holstein-Friesian cows from the herd at the study site. Individual animals were identified by the unique 123 
number on their official primary ear tag and were also marked as study participants using coloured tail 124 
tape. All cows included received a physical examination, including assessment of the respiratory, 125 
cardiovascular, gastrointestinal, musculoskeletal and reproductive systems as well as skin, udder and 126 
teats. The physical examination included body condition score, pulse rate, respiration rate and a rectal 127 
temperature conducted by a licensed veterinarian or trained designee approximately 7 days prior to their 128 
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anticipated calving date. All animals had body condition scores between 2.5 and 3.5 (Wildman et al., 129 
1982). Animals exhibiting abnormal clinical signs that could be anticipated to have an impact on the 130 
expected calving or uterine health and cattle undergoing any surgical or medical treatment 30 days before 131 
the trial, as well as animals carrying more than one calf, were not enrolled in the study. 132 
The experimental unit for all variables was the individual animal. A treatment administrator 133 
allocated the animals to treatment or placebo groups using a random selection program written in R and 134 
delivered the assigned treatments. Cows in the treatment group received two doses of Imrestor™ (Elanco 135 
Animal Health, Basingstoke, UK) as indicated on the product leaflet. Animals in the placebo group were 136 
injected with the same volume of sterile saline (Steripod, Mölnlycke Health Care) subcutaneously. The 137 
treatment data were stored in a secure location and the scientists taking the blood sample as well as 138 
conducting the in vitro assessments were kept blinded until the completion of the statistical analysis. 139 
After excluding one cow in the placebo group due to calving outside of the prescribed treatment window 140 
of 17 days, 11 animals finished the study. One animal gave birth overnight between days 17 and 18 and 141 
was included in the analysis described in this paper. 142 
Calving dates (study day 0) were estimated based on service date records. Nine days before 143 
anticipated calving (study day -9), whole blood and serum samples were collected, using the Vacutainer 144 
system with EDTA-treated and plain tubes (Becton Dickinson). EDTA blood was submitted to the 145 
Diagnostic Laboratories of the Royal Veterinary College for complete blood count (CBC) using an 146 
automated Advia 2120i system (Siemens) and microscopic blood smear analysis with manual 147 
differential count. The serum sample was submitted for measurement of non-esterified fatty acid (NEFA) 148 
to the Animal and Plant Health Agency laboratory (Shrewsbury, Shropshire, UK). Animals identified to 149 
have NEFA levels elevated above 400 μmol/L (Oetzel, 2003) were to be removed from the study. On 150 
study day -7, the animals received their first treatment. Health observations were made once daily from 151 
here on to completion of the animal. Two days later, on day -5, an additional EDTA blood sample was 152 
collected and submitted for haematological analysis as described above. Within 24 hours of actual 153 
calving (study day 0), the second treatment was administered and two days later (study day +2), 24 mL 154 
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EDTA blood was collected for haematological analysis and to isolate granulocytes for setting up in vitro 155 
functional assays. Β-hydroxy-butyric acid (BHBA) testing was also performed using fresh whole blood 156 
on all sampling days using the Precision Xtra Blood Glucose and Ketone Monitoring System (Precision) 157 
with Precision Xtra Blood Ketone Test Strips (Abbott). 158 
The in vitro assessments of granulocyte function were split into two sections measuring 159 
bactericidal activity and directed migratory function of granulocytes. Granulocytes were isolated by 160 
density centrifugation of EDTA blood (Munoz-Caro et al., 2015a, Munoz-Caro et al., 2015b) collected 161 
by venepuncture of jugular vein from study animals two days after calving. Granulocyte isolation was 162 
started within one hour of sampling in all cases. After cell separation and counting, the cell 163 
concentrations were set to 2x106/mL for each sample, and cells passed on to another scientist blinded to 164 
the original cell counts, to set up the migration and bactericidal assays. 165 
The bacterial strain used for in vitro functional assays was Escherichia coli strain MS499, which 166 
has recently been described as a prototypic endometrial pathogenic E. coli strain (Goldstone et al., 2014a, 167 
Goldstone et al., 2014b). E. coli MS499 was freshly plated from cryopreserved stock every week. For 168 
each migration and bactericidal assay, single colonies were selected and cultured, then diluted 169 
appropriately to ensure a multiplicity of infection (MOI) of ten with regards to granulocyte numbers.  170 
Primary bovine endometrium epithelial cells were cultured using uteruses collected from two 171 
clinically healthy Holstein-Friesian cows post mortem at an abattoir (Dawn Cardington, Meadow Ln, 172 
Bedford, UK). Endometrial cultures, consisting of epithelial (>95%) and stromal cells were isolated 173 
using the differential attachment plating method after trypsin/collagenase digestion of endometrium 174 
tissue, as described elsewhere (Cheng et al., 2013). Cells were cultured to at least 75% confluency in 175 
anticipation of calving. Primary endometrium cultures from at least two animals were used in duplicates 176 
for each assay condition. 177 
General migratory function and migration towards compromised epithelial cells were assessed by 178 
placing granulocytes (1 x 106) into the upper chamber of a transwell system (24 well plate) with a pore 179 
size of 3.0 µm (Greiner Bio One). Granulocytes migrated through these pores towards stimuli in the 180 
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lower chambers of the plates, where the following conditions were present: i) a monolayer of primary 181 
endometrium culture ii) a monolayer of primary endometrium culture, infected with E. coli MS499 at 182 
an MOI of 10 relative to the number of granulocytes, iii) E. coli MS499 bacteria only, iv) positive 183 
migration control (10 ng/mL recombinant bovine CXCL8) and v) spontaneous migration control 184 
(Roswell Park Memorial Institute medium (RPMI) only). Each condition was set up in duplicate. 185 
Migrating granulocytes were counted from the lower chamber using a FastRead chamber slide (Immune 186 
Systems) after 3 and 24 hours, by counting in 4 grids per replicate. In the bactericidal assays, 187 
granulocytes were co-cultured with MS499 at a MOI of 10 for 3 hours at 37 °C before removing cell 188 
culture media. One set of cells (3 hour-time point) were washed twice with Gentamycin (50 mg/mL, 189 
Sigma Aldrich) and lysed with Triton X100 (0.1%). Supernatants were plated for subsequent CFU counts 190 
by serial dilution on LB Agar to assess the number of viable phagocytosed bacteria. Another set of cells 191 
(24 hour-time point) were washed twice, and Gentamycin was added to granulocyte media. These cells 192 
were cultured for further 21 hours, followed by lysis. Lysates were plated for CFU counts as described 193 
above. 194 
The full reproducible protocols of in vitro migration and bactericidal assays are detailed in 195 
Supplementary material A. WBC data were assessed for normal distribution, and biologically relevant 196 
comparisons were made between subsequent timepoints of data from one treatment group and between 197 
treatment groups at the same timepoints, using T-test in Prism v. 5 (GraphPad Software). 198 
 199 
RESULTS AND DISCUSSION 200 
The blood tests performed at day -9, two days before the first treatment, confirmed that all animals 201 
met the inclusion criteria regarding NEFA levels, and no significant difference in NEFA values were 202 
observed between animals enrolled in either study group (Figure 1A). 203 
Pegbovigrastim treatment increased the overall WBC concentration as well as the concentration 204 
of circulating neutrophil granulocytes and monocytes, but did not affect the concentration of circulating 205 
lymphocytes. At day -9, two days before the first treatment, there were no significant differences for the 206 
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total concentration of WBC, neutrophil granulocytes, monocytes or lymphocytes (Figure 1C-F, Day -9). 207 
Two days after the first treatment, at day-5, WBC concentration, the concentration of circulating 208 
neutrophil granulocytes and monocytes, but not that of lymphocytes was increased in treated animals. 209 
These concentrations increased even further by the last sampling (day +2). In pegbovigrastim-treated 210 
animals, the increase in total WBC concentration was significant between all timepoints (p<0.01 day -9 211 
to -5 and p=0.03 day -5 to 2). Differences were also significant between treated and placebo groups at 212 
both timepoints after the first treatment (p<0.01 on day -5 and p=0.03 on day 2). The elevation of total 213 
WBC concentration was reflected in neutrophil and monocyte concentration, with significant increase 214 
in neutrophil granulocyte concentrations compared to before treatment (day -5 p<0.01) and placebo 215 
counts (day -5, p<0.01). Monocyte concentration showed significant responses to treatment (p=0.01 by 216 
day -5 and p<0.01 by day 2), reaching a significant difference to cells from placebo-treated animals on 217 
day 2 (p<0.01). In contrast, no significant increases in the total concentration of monocytes and 218 
granulocytes were seen in the control group at any timepoint. 219 
Interestingly, our results demonstrated a clear increase in absolute numbers of both myeloid cell 220 
subsets (and therefore also WBC) in pegbovigrastim-treated animals as early as two days after the first 221 
treatment, even in this small cohort of animals. However, it is noted that this effect is not homogenous 222 
in all animals in our study, as one animal did not respond to the same extent.  223 
Contrary to results in other studies (Kimura et al., 2014), using our study protocol, we did not see 224 
a decrease in WBC and neutrophil granulocyte concentration in placebo-treated control animals, or an 225 
increase in circulating lymphocytes in pegbovigrastim treated animals, as described by (Powell et al., 226 
2018). Since genetically all animals used on the study were high-producing Holstein-Friesian dairy 227 
cattle, the maintenance of leukocyte numbers throughout parturition is probably due to a less marked 228 
negative energy balance, caused by the management practices on the smaller-scale study farm where the 229 
trial was conducted. This is in line with the result that none of the animals had NEFA levels above 400 230 
μmol/L (Figure 1A), nor BHBA levels elevated above 1.4 mmol/L (Figure 1B), indicating the absence 231 
of subclinical ketosis (Oetzel, 2003). 232 
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Alongside fully mature granulocytes, band neutrophils were also released into circulation in four 233 
out of six animals after the first, and in all cows after the second pegbovigrastim treatment (Figure 1G). 234 
In one treated animal, metamyelocytes appeared in peripheral blood on day 2. In contrast, band 235 
neutrophils were measured in only one animal in the placebo control group after the second injection. 236 
This is a known effect of G-CSF treatment in cattle (Kehrli et al., 1991, Detilleux et al., 1995). 237 
Bacterial survival was not impacted by pegbovigrastim treatment on a per cell base (Figure 2A). 238 
As granulocytes from pegbovigrastim treated animals have been described to show a higher 239 
myeloperoxidase activity, which could increase bacterial killing, we were interested to assess differences 240 
in bactericidal activity of granulocytes exposed to E. coli bacteria from either treatment group. Neither 241 
at 3h incubation nor at 24h did the amounts of surviving bacteria recovered from lysed granulocytes 242 
show a significant difference, indicating similar bactericidal rates between both groups. 243 
Granulocytes from either treated or untreated cows were also assessed in their ability to migrate 244 
towards isolated endometrial cells, E. coli infected endometrial cells, E. coli alone or towards CXCL8. 245 
Overall, the number of granulocytes that migrated under any condition was numerically greater (no 246 
significant differences) after 24h compared to those values obtained in the same condition after 3h 247 
(Figures 2B, 2C). The number of migrated granulocytes was greater under all conditions tested compared 248 
to the negative (medium alone) control, however, no significant differences between granulocytes 249 
isolated from pegbovigrastim treated or untreated animals were seen at 3h or 24h. The number of 250 
granulocytes showing random migration (negative control, RPMI only) was lower than in any other 251 
condition. It was recently described that pegbovigrastim treatment increased the expression of genes 252 
involved in granulocyte migration/function (Heiser et al., 2018). However, as these changes were not 253 
confirmed by flow cytometry or ex vivo functional assays, our data may not be regarded as contradictory 254 
to these observations. 255 
To determine whether cells generated from uteruses of different animals affected migration, 256 
primary cells from two animals were used. These animals were in slightly different stages of their oestrus 257 
cycles, one just after ovulation with corpus haemorrhagicum present and the other one having a well-258 
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developed corpus luteum. Differences in the number of migrating granulocytes were assessed between 259 
the results obtained for cells generated from treated or untreated cows to either endometrial epithelium 260 
cells alone, or endometrial cells infected with E. coli strain MS499, at 3 as well as 24 hours, in a T-test 261 
paired for each condition. There was no significant difference detectable between the results of the two 262 
endometrium cultures (p=0.7114, mean of differences=1.6x105 migrated cells/mL, not shown). The 263 
source of tissue did not affect the outcome of the results obtained, in line with observations that in vitro 264 
cultures of endometrial epithelial and stromal cells have been described to mount innate immune 265 
responses to E. coli independently of the stage of oestrus cycle (Saut et al., 2014). 266 
Pegbovigrastim is described currently to have its most beneficial effects during the period of negative 267 
energy balance, where neutrophil numbers are decreased. It may be possible that a negative energy 268 
balance causes oxidative stress, inhibiting granulocyte function (Kuwabara et al., 2015), which could be 269 
exacerbated by the presence of ketone bodies during this period (Hoeben et al., 1997). However, in 270 
general, our observations indicate that granulocytes generated from both study groups are readily able 271 
to migrate to endometrial cells in a transwell system. Furthermore, we observed no differences in 272 
granulocyte function between negative controls (cells incubated with media alone) and cells exposed to 273 
treatment. Our results do not indicate decreased or enhanced function of granulocytes isolated from 274 
pegbovigrastim-treated cows compared to granulocytes isolated from control-treated cows on a per-cell 275 
base. In our study, placebo-treated animals maintained WBC concentrations throughout the experiment, 276 
and granulocytes remained functional for the parameters tested. As our study was performed using 277 
healthy cows, it remains to be seen whether effects of pegbovigrastim treatment on neutrophil 278 
functionality may have been different in animals with negative energy balance, hypocalcemia, any other 279 
form of stress, or in animals with reduced neutrophil concentrations in future studies. 280 
 281 
ACKNOWLEDGEMENTS 282 
We would like to thank Dr. Daniel Hampshire, Marie-Christine Bartens, and Dawn Meats for 283 
technical assistance. Furthermore, we would like to thank the staff of RVC Bolton Park farm for 284 
12 
 
collaboration and help, especially Ms Charlotte Verity. The study was funded by a grant to DW from 285 
Elanco Animal Health UK, covering salary for KT and costs of consumables. This manuscript represents 286 
publication PPS_01959 of the RVC.  287 
 288 
REFERENCES 289 
Canning, P., R. Hassfurther, T. TerHune, K. Rogers, S. Abbott, and D. Kolb. 2017. Efficacy and 290 
clinical safety of pegbovigrastim for preventing naturally occurring clinical mastitis in periparturient 291 
primiparous and multiparous cows on US commercial dairies. Journal of Dairy Science 100(8):6504-292 
6515. 293 
Carneiro, L. C., J. G. Cronin, and I. M. Sheldon. 2016. Mechanisms linking bacterial infections of the 294 
bovine endometrium to disease and infertility. Reprod Biol 16(1):1-7. 295 
Cheng, Z., D. R. Abayasekara, F. Ward, D. M. Preece, K. A. Raheem, and D. C. Wathes. 2013. 296 
Altering n-3 to n-6 polyunsaturated fatty acid ratios affects prostaglandin production by ovine uterine 297 
endometrium. Anim Reprod Sci 143(1-4):38-47. 298 
Conejeros, I., A. J. Gibson, D. Werling, T. Munoz-Caro, C. Hermosilla, A. Taubert, and R. A. Burgos. 299 
2015. Effect of the synthetic Toll-like receptor ligands LPS, Pam3CSK4, HKLM and FSL-1 in the 300 
function of bovine polymorphonuclear neutrophils. Dev Comp Immunol 52(2):215-225. 301 
Cronin, J. G., V. Kanamarlapudi, C. A. Thornton, and I. M. Sheldon. 2016. Signal transducer and 302 
activator of transcription-3 licenses Toll-like receptor 4-dependent interleukin (IL)-6 and IL-8 303 
production via IL-6 receptor-positive feedback in endometrial cells. Mucosal Immunol 9(5):1125-304 
1136. 305 
Detilleux, J. C., M. E. Kehrli, Jr., J. R. Stabel, A. E. Freeman, and D. H. Kelley. 1995. Study of 306 
immunological dysfunction in periparturient Holstein cattle selected for high and average milk 307 
production. Vet Immunol Immunopathol 44(3-4):251-267. 308 
Freick, M., M. Zenker, O. Passarge, and J. Weber. 2018. Reducing the incidence of acute puerperal 309 
metritis in primiparous cows by application of pegbovigrastim in a Holstein dairy herd. Veterinarni 310 
Medicina 63(04):151-160. 311 
Gibson, A. J., S. Woodman, C. Pennelegion, R. Patterson, E. Stuart, N. Hosker, P. Siviter, C. Douglas, 312 
J. Whitehouse, W. Wilkinson, S. A. Pegg, B. Villarreal-Ramos, and D. Werling. 2016. Differential 313 
macrophage function in Brown Swiss and Holstein Friesian cattle. Vet Immunol Immunopathol 314 
181:15-23. 315 
Goldstone, R. J., R. Popat, H. J. Schuberth, O. Sandra, I. M. Sheldon, and D. G. Smith. 2014a. 316 
Genomic characterisation of an endometrial pathogenic Escherichia coli strain reveals the acquisition 317 
of genetic elements associated with extra-intestinal pathogenicity. BMC Genomics 15:1075. 318 
Goldstone, R. J., R. Talbot, H. J. Schuberth, O. Sandra, I. M. Sheldon, and D. G. Smith. 2014b. Draft 319 
Genome Sequence of Escherichia coli MS499, Isolated from the Infected Uterus of a Postpartum Cow 320 
with Metritis. Genome Announc 2(4). 321 
Grinberg, N., S. Elazar, I. Rosenshine, and N. Y. Shpigel. 2008. Beta-hydroxybutyrate abrogates 322 
formation of bovine neutrophil extracellular traps and bactericidal activity against mammary 323 
pathogenic Escherichia coli. Infection and immunity 76(6):2802-2807. 324 
Hammon, D. S., I. M. Evjen, T. R. Dhiman, J. P. Goff, and J. L. Walters. 2006. Neutrophil function 325 
and energy status in Holstein cows with uterine health disorders. Vet Immunol Immunopathol 113(1-326 
2):21-29. 327 
Heiser, A., S. J. LeBlanc, and S. McDougall. 2018. Pegbovigrastim treatment affects gene expression 328 
in neutrophils of pasture-fed, periparturient cows. J Dairy Sci 101(9):8194-8207. 329 
13 
 
Hoeben, D., R. Heyneman, and C. Burvenich. 1997. Elevated levels of beta-hydroxybutyric acid in 330 
periparturient cows and in vitro effect on respiratory burst activity of bovine neutrophils. Vet Immunol 331 
Immunopathol 58(2):165-170. 332 
Hoeben, D., E. Monfardini, G. Opsomer, C. Burvenich, H. Dosogne, A. De Kruif, and J. F. Beckers. 333 
2000. Chemiluminescence of bovine polymorphonuclear leucocytes during the periparturient period 334 
and relation with metabolic markers and bovine pregnancy-associated glycoprotein. J Dairy Res 335 
67(2):249-259. 336 
Jensen, K., I. J. Gallagher, A. Kaliszewska, C. Zhang, O. Abejide, M. P. Gallagher, D. Werling, and E. 337 
J. Glass. 2016. Live and inactivated Salmonella enterica serovar Typhimurium stimulate similar but 338 
distinct transcriptome profiles in bovine macrophages and dendritic cells. Vet Res 47:46. 339 
Joekel, D., P. Hinse, M. K. Raulf, S. Schicht, W. Baumer, D. Werling, E. Kremmer, and C. Strube. 340 
2015. Vaccination of calves with yeast- and bacterial-expressed paramyosin from the bovine 341 
lungworm Dictyocaulus viviparus. Parasite Immunol 37(12):614-623. 342 
Kehrli, M. E., Jr., J. P. Goff, M. G. Stevens, and T. C. Boone. 1991. Effects of granulocyte colony-343 
stimulating factor administration to periparturient cows on neutrophils and bacterial shedding. J Dairy 344 
Sci 74(8):2448-2458. 345 
Kehrli, M. E., Jr., B. J. Nonnecke, and J. A. Roth. 1989. Alterations in bovine neutrophil function 346 
during the periparturient period. Am J Vet Res 50(2):207-214. 347 
Kimura, K., J. P. Goff, P. Canning, C. Wang, and J. A. Roth. 2014. Effect of recombinant bovine 348 
granulocyte colony-stimulating factor covalently bound to polyethylene glycol injection on neutrophil 349 
number and function in periparturient dairy cows. Journal of Dairy Science 97(8):4842-4851. 350 
Kuwabara, W. M., L. Zhang, I. Schuiki, R. Curi, A. Volchuk, and T. C. Alba-Loureiro. 2015. NADPH 351 
oxidase-dependent production of reactive oxygen species induces endoplasmatic reticulum stress in 352 
neutrophil-like HL60 cells. PLoS One 10(2):e0116410. 353 
Munoz-Caro, T., M. Lendner, A. Daugschies, C. Hermosilla, and A. Taubert. 2015a. NADPH oxidase, 354 
MPO, NE, ERK1/2, p38 MAPK and Ca2+ influx are essential for Cryptosporidium parvum-induced 355 
NET formation. Developmental and comparative immunology 52(2):245-254. 356 
Munoz-Caro, T., S. J. Mena Huertas, I. Conejeros, P. Alarcon, M. A. Hidalgo, R. A. Burgos, C. 357 
Hermosilla, and A. Taubert. 2015b. Eimeria bovis-triggered neutrophil extracellular trap formation is 358 
CD11b-, ERK 1/2-, p38 MAP kinase- and SOCE-dependent. Veterinary research 46:23. 359 
Nicola, N. A. and D. Metcalf. 1986. Specificity of action of colony-stimulating factors in the 360 
differentiation of granulocytes and macrophages. Ciba Found Symp 118:7-28. 361 
Oetzel, G. R. 2003. Herd-Based Biological Testing For Metabolic Disorders. in American Association 362 
of Bovine Practitioners 36th Annual Conference. Columbus, Ohio, USA. 363 
Powell, E. J., T. A. Reinhardt, E. Casas, and J. D. Lippolis. 2018. The effect of pegylated granulocyte 364 
colony-stimulating factor treatment prior to experimental mastitis in lactating Holsteins. J Dairy Sci 365 
101(9):8182-8193. 366 
Pyorala, S., J. Taponen, and T. Katila. 2014. Use of antimicrobials in the treatment of reproductive 367 
diseases in cattle and horses. Reprod Domest Anim 49 Suppl 3:16-26. 368 
Ruiz, R., L. O. Tedeschi, and A. Sepúlveda. 2017. Investigation of the effect of pegbovigrastim on 369 
some periparturient immune disorders and performance in Mexican dairy herds. Journal of Dairy 370 
Science 100(4):3305-3317. 371 
Saut, J. P., G. D. Healey, A. M. Borges, and I. M. Sheldon. 2014. Ovarian steroids do not affect bovine 372 
endometrial cytokine or chemokine responses to Escherichia coli or LPS in vitro. Reproduction 373 
148(6):593-606. 374 
Wildman, E. E., G. M. Jones, P. E. Wagner, R. L. Boman, H. F. Troutt, Jr., and T. N. Lesch. 1982. A 375 
Dairy Cow Body Condition Scoring System and Its Relationship to Selected Production 376 
Characteristics. Journal of Dairy Science 65(3):495-501. 377 
Zinicola, M., H. Korzec, A. G. V. Teixeira, E. K. Ganda, L. Bringhenti, A. Tomazi, R. O. Gilbert, and 378 
R. C. Bicalho. 2018. Effects of pegbovigrastim administration on periparturient diseases, milk 379 
production, and reproductive performance of Holstein cows. J Dairy Sci 101(12):11199-11217. 380 
 381 
14 
 
 382 
15 
 
N E F A

m
o
l/
L
t re a tm e n t p la c e b o
0
1 0 0
2 0 0
3 0 0
4 0 0
B H B A
m
m
o
l/
L
0 .2
0 .4
0 .6
0 .8
1 .0
tre a tm e n t
p la c e b o
D ay  -9 D ay  -5 D ay  2
1
0
9
c
e
ll
s
/L
0
2 0
4 0
6 0
8 0
W h ite  b lo o d  c e lls
tre a tm e n t
p la c e b o
D ay  -9 D ay  -5 D ay  2
* *
* *
*
*
1
0
9
c
e
ll
s
/L
-2 0
0
2 0
4 0
6 0
8 0
N e u tro p h il g ra n u lo c y te s
tre a tm e n t
p la c e b o
D ay  -9 D ay  -5 D ay  2
* *
* *
1
0
9
c
e
ll
s
/L
0
2
4
6
8
L y m p h o c y te s
D ay  -9 D ay  -5 D ay  2
p la c e b o
tre a tm e n t
1
0
9
c
e
ll
s
/L
0
2
4
6
8
M o n o c y te s
p la c e b o
tre a tm e n t
D ay  -9 D ay  -5 D ay  2
*
* *
**
1
0
9
c
e
ll
s
/L
0
1
2
3
4
B a n d  n e u tro p h ils
tre a tm e n t
p la c e b o
D ay  -9 D ay  -5 D ay  2
A B
C
E
D
F
G
383 
Tombacz, Figure 1. 384 
16 
 
Figure 1. Ex vivo parameters measured in study groups. Dot plot diagram showing A) NEFA levels 385 
measured in study groups nine days before estimated parturition, B) BHBA levels measured at three 386 
timepoints, C) WBC, D) Neutrophil granulocyte, E) Lymphocyte, F) Monocyte concentrations measured 387 
at three timepoints. G) Dot plot of band neutrophil concentrations measured in study groups. Group 388 
mean and SD values are listed in Supplementary material B for each parameter. 389 
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Figure 2. In vitro assay results. A) Bactericidal assay. Dot plots showing individual values and geometric 393 
means of colony forming units (CFU+1)/mL of E. coli MS499 surviving intracellular killing after 3 and 394 
24 hours of incubation. For the purpose of representing zero values on a logarithmic scale, 1 was added 395 
to all mean CFU counts. B) Dot plot: migration of granulocytes from pegbovigrastim and placebo treated 396 
animals towards endometrium and infected endometrium. C) Results of migration assay controls. Dot 397 
plot of migrated cells towards MS499 E. coli, 10 ng/mL CXCL8 and media only control. Group mean 398 
and SD values are listed in Supplementary material C for each parameter. 399 
